Amneal Pharmaceuticals Inc (NYSE:AMRX) Shares Sold by Bank of Montreal Can

Bank of Montreal Can lessened its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 86.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,521 shares of the company’s stock after selling 28,234 shares during the period. Bank of Montreal Can’s holdings in Amneal Pharmaceuticals were worth $64,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Bessemer Group Inc. purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $34,000. Quantamental Technologies LLC purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $68,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Amneal Pharmaceuticals by 28.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock valued at $91,000 after purchasing an additional 1,477 shares during the period. Meeder Asset Management Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 785.6% in the first quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after purchasing an additional 10,347 shares during the period. Finally, Amalgamated Bank purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $174,000. 36.05% of the stock is owned by institutional investors and hedge funds.

In other Amneal Pharmaceuticals news, SVP Joseph Todisco purchased 15,000 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was bought at an average price of $9.88 per share, with a total value of $148,200.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Pradeep Bhadauria purchased 7,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $8.48 per share, with a total value of $59,360.00. The disclosure for this purchase can be found here. Insiders purchased a total of 41,000 shares of company stock valued at $387,300 in the last quarter. 26.34% of the stock is owned by insiders.

AMRX has been the subject of a number of analyst reports. SunTrust Banks initiated coverage on Amneal Pharmaceuticals in a report on Tuesday, March 19th. They set a “buy” rating and a $16.00 target price for the company. Barclays assumed coverage on Amneal Pharmaceuticals in a research report on Tuesday, June 11th. They set an “equal weight” rating and a $9.00 price target on the stock. Zacks Investment Research raised Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Svb Leerink downgraded Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the company from $16.00 to $12.00 in a research report on Friday, March 8th. Finally, Leerink Swann downgraded Amneal Pharmaceuticals to a “market perform” rating in a research report on Friday, March 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $16.73.

AMRX stock traded down $0.07 during mid-day trading on Monday, reaching $7.10. The company’s stock had a trading volume of 1,183,900 shares, compared to its average volume of 1,062,575. The stock has a market cap of $2.14 billion, a PE ratio of 7.47, a PEG ratio of 0.44 and a beta of 1.51. The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.37 and a current ratio of 2.11. Amneal Pharmaceuticals Inc has a fifty-two week low of $6.23 and a fifty-two week high of $24.48. The company’s 50 day moving average price is $7.90.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.07). Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The firm had revenue of $446.00 million for the quarter, compared to analyst estimates of $438.18 million. The business’s quarterly revenue was up 4.9% on a year-over-year basis. On average, research analysts forecast that Amneal Pharmaceuticals Inc will post 0.91 earnings per share for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Story: Is a Roth IRA right for you?

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.